


Call for Expressions of Interest

Postdoctoral/Master fellow – Tsoumakidou Lab | BSRC Fleming

The laboratory of Dr. Maria Tsoumakidou (Tsoumakidou Lab) at the Biomedical Sciences Research Center 'Alexander Fleming' (www.fleming.gr) is seeking a Postdoctoral/Master Fellow. The lab focuses on cancer immunity and studies in parallel human and mouse systems, using laboratory and computational experimental approaches. Candidates must hold a PhD or MSc and have excellent command of the English language. Experience in tissue imaging is desirable.



The successful applicants will specifically work towards understanding the cellular and molecular networks that dictate the outcomes of cancer antigen presentation.

Expressions of interest should be sent electronically to **tsoumakidou@fleming.gr**. Candidates should email a cover letter outlining their interests and areas of expertise (maximum 1 page long), together with detailed curriculum vitae, including contact information of two referees.

Deadline for expression of interest: 21 October 2022

BSRC Fleming is a top-ranked Greek non-profit research organization focusing on scientific and technological excellence, training and innovation in biomedical sciences. The Center was established in 1998, and operates under the supervision of the General Secretariat for Research and Technology (GSRT) of the Hellenic Ministry of Education. Competitive funding each year amounts to 75-85% of the total budget of the Center, an achievement that underlies Fleming's strategic prioritization of research and innovation. The Center has gained international recognition for its pioneering research towards understanding the molecular and cellular basis of human diseases such as autoimmune diseases, cancer, neurodegenerative disorders, osteoporosis, pulmonary fibrosis and others, and the development of new approaches for their diagnosis and treatment. Fleming's strength and international visibility lies on its focus and success in developing and characterizing animal models that mimic human disease and the Center has consequently invested heavily on related infrastructures.